AbbVie Inc. appears well positioned to maintain the US commercial exclusivity of its blockbuster autoimmune disease drug Humira (adalimumab) for 20 years from its launch, many of those years as the world's top-selling drug. The company announced the resolution of a second patent dispute April 5, this time with Samsung Bioepis Co. Ltd., which will protect Humira's market exclusivity in the US until June 30, 2023.
In Europe, Samsung's biosimilar version of Humira can launch earlier, on Oct. 16, 2018